Ivana S. G.
- Country
- Croatia
- Department
- NA
Research Overview
- A Dose-Finding Study to Evaluate the Efficacy and Safety of Once-Weekly Subcutaneous NNC0662-0419 in Participants with Type 2 Diabetes
- Efficacy and safety of subcutaneous once-weekly zenagamtide in participants with overweight or obesity and type 2 diabetes
- Efficacy and safety of zenagamtide versus semaglutide in participants with overweight or obesity and type 2 diabetes
Data & Insights
Has run more than one trial at 86 of 257 partner sites.
Specializations
Metabolic Disorders
The investigator specializes in the study and treatment of severe hypertriglyceridemia (SHTG), a serious metabolic condition characterized by abnormally high levels of triglycerides in the blood.
- Lipid metabolism disorders
- Triglyceride level management
- Cardiovascular risk reduction
Their research focuses on innovative therapeutic approaches for managing elevated triglyceride levels in adult patients.
Therapeutic Innovation
The investigator explores novel therapeutic agents targeting lipid metabolism pathways, with particular attention to treatments that can effectively reduce fasting serum triglyceride levels.
- Novel therapeutic compounds
- Metabolic pathway modulation
- Treatment optimization
Their work encompasses the evaluation of emerging treatments for severe metabolic disorders affecting lipid regulation.
Clinical Assessment
The investigator conducts comprehensive evaluations of therapeutic interventions for metabolic disorders, focusing on their efficacy in managing severe lipid abnormalities.
- Treatment efficacy assessment
- Patient response monitoring
- Clinical outcomes evaluation
Their expertise extends to measuring therapeutic effectiveness in patients with severe metabolic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.